Increasing
Incidence Of Pancreatic Cancer Leading To A $6.85 Billion Dollar Market Size
For New Treatments; @FNMgroup @Oncolytics
Palm
Beach, FL – March 5, 2024 – FN Media Group News
Commentary – Pancreatic cancer is one of the leading causes of
cancer death globally. The increasing incidence of this cancer across the U.S.
and other parts of the world is one of the factors driving the need for the
drugs used in the treatment. Moreover, the prevalence is significantly higher
in the geriatric population compared to other types of cancers. Thus, an
increase in the geriatric population is one factor driving the pancreatic
cancer treatment market growth. The incidence is significantly higher in the geriatric
population above 65 years of age compared to other types of cancers. A report from
Fortune Business Insights said that: “the pancreatic cancer treatment market
size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of
15.7% during 2022-2029. North America dominated the global market with a share
of 46.97% in 2022. The increase in the number of patients suffering from the
condition has increased the demand for the drugs used in treatment. These are
some factors driving the growth during the forecast period. Companies
engaged in manufacturing cancer drugs have increased their focus on R&D
activities to develop new drugs for pancreatic cancer treatment. Additionally,
the companies operating in the market have received approval from several
regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the
Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others,
thereby propelling the growth of the market. Moreover, new testing technologies
are being adopted by hospitals and diagnostic centers to diagnose cancer. The
increase in the diagnosis rates is driving the demand for drugs, thereby
providing opportunities for the players.” Active biotech and pharma
companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ:
ONCY) (TSX: ONC), Ocean Biomedical, Inc. (NASDAQ: OCEA), LAVA
Therapeutics N.V. (NASDAQ: LVTX), Merck
& Co., Inc. (NYSE: MRK), AbbVie
Inc. (NYSE: ABBV).
Read this in full at https://www.financialnewsmedia.com/increasing-incidence-of-pancreatic-cancer-leading-to-a-6-85-billion-dollar-market-size-for-new-treatments/
Fortune Business Insights continued: “Shifting the focus of key
players in extensive R&D activities to develop new drugs and an increase in
funding for cancer research led to the development of new drugs for treatment.
Additionally, several pharmaceutical companies are involved in clinical trials
to develop new drugs and explore the potential of the molecule to treat the
disease. Thus, with the increased funding for R&D activities,
companies are focused on developing new drugs, thereby contributing to the
overall rise in demand for drugs for pancreatic type of cancer treatment. Thus,
increasing aging population and rising government initiatives to create
awareness for the diagnosis of the condition are some factors propelling the
market growth.”
Oncolytics Biotech® Inc. (NASDAQ:
ONCY) (TSX: ONC) Files Amendment to Initiate New Pancreatic Cancer GOBLET
Cohort Supported by PanCAN – US$5M grant supports study of
pelareorep in combination with modified FOLFIRINOX +/- atezolizumab – Oncolytics
Biotech® Inc., a clinical-stage immunotherapeutics company focused on oncology,
today announced it has submitted an amendment to GOBLET to initiate a new Phase
1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX
(mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly
diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment
will be reviewed by the Paul Ehrlich Institute (PEI; Germany’s regulatory body)
for approval before patient enrollment can begin. The cohort, the fifth of the
GOBLET gastrointestinal cancer study, is being supported by the US$5 million
Therapeutic Accelerator Award from the Pancreatic Cancer Action Network
(PanCAN), an innovative program established to accelerate the development of
new treatments for pancreatic cancer.
“We are enthusiastic to have the support of PanCAN to expand the
evaluation of pelareorep in pancreatic cancer and explore mFOLFIRINOX as
another combination that could improve outcomes for patients. Notably, this
patient population is newly diagnosed patients who are receiving first-line
treatment. Chemotherapies, including either mFOLFIRINOX or gemcitabine and
nab-paclitaxel, are the backbone treatment regimens of pancreatic cancer
therapy. Evaluating pelareorep in combination with these widely used regimens
is an important step in our broad clinical development program,” said Dr. Matt
Coffey, President and Chief Executive Officer of Oncolytics. “Last fall, we
reported a 62% objective response rate for the GOBLET PDAC cohort studying
pelareorep in combination with the checkpoint inhibitor atezolizumab in addition
to gemcitabine and nab-paclitaxel (link to the PR, link to the poster).
This response is about three times that of historical controls and forms the
basis of the registrational program, expected to begin this year. Therefore, we
are enthusiastic about this new mFOLFIRINOX pancreatic cancer cohort and look
forward to enrolling the first patient as soon as possible.”
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum
Hamburg, and primary investigator of the GOBLET trial, commented, “One of the
reasons for pancreatic cancer’s poor survival rate is that it effectively
evades the immune system and can induce an immunosuppressive tumor
microenvironment (TME). Pelareorep is an attractive combination partner because
of its ability to address both issues by activating the innate and adaptive
immune systems while driving the remodeling of the tumor microenvironment.
Positive results from the Phase 2 study evaluating pelareorep combined with
atezolizumab and chemotherapy reported last fall support the potential use of
these agents together. I am hopeful that the combination of pelareorep and
mFOLFIRINOX (with or without atezolizumab) will yield positive response data
and advance the development of new treatment options for patients with
pancreatic cancer.”
“This study is designed to evaluate whether pelareorep can
enhance outcomes in patients receiving mFOLFIRINOX, one of the most commonly
used metastatic pancreatic cancer treatments. Combining pelareorep with
mFOLFIRINOX represents an expansion of our existing pancreatic cancer program
and maximizes the potential of pelareorep-based combination therapies to
benefit pancreatic cancer patients,” commented Thomas Heineman, M.D., Ph.D.,
Chief Medical Officer at Oncolytics. “The mFOLFIRINOX cohort utilizes a
screened selection design within a Simon two-stage approach that will also
allow evaluation of the contribution of atezolizumab to the
pelareorep/mFOLFIRINOX combination. In addition, this study is designed to
provide valuable translational assessments, such as the expansion of
tumor-infiltrating lymphocytes (TILs) in the blood, which has been associated
with tumor responses. We look forward to building on PanCAN’s strong
relationships with the pancreatic cancer community and furthering our collaboration
with AIO-Studien-gGmbH (AIO) on the GOBLET study.” CONTINUED… Read
these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/
Other recent developments in
the biotech industry of note for cancer events include:
Ocean Biomedical, Inc.
(NASDAQ: OCEA), a biopharma company which endeavors
to accelerate the development of compelling discoveries from top research
scientists, recently congratulated its joint venture partner,
Virion Therapeutics, LLC, a clinical-stage biotechnology company
developing T cell-based immunotherapies, for the acceptance of their
abstract highlighting the first-ever human data from its novel checkpoint
modifier immunotherapy for HBV functional cure, for late breaker oral
presentation at the upcoming 33rd Annual Meeting of
APASL (The Asian Pacific Association for the Study of the Liver), taking
place in Kyoto, Japan from March 27-31, 2024.
The late breaker presentation will highlight the safety data
observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200. “This
accepted abstract highlights Virion’s commitment to finding a functional cure
for chronically HBV-infected patients – and the first-ever human data for a
genetically encoded checkpoint modifier T cell vaccine of any kind. VRON-0200
is uniquely developed to stimulate a patient’s own immune response to the
virus. Additionally, its mechanism of action and intramuscular administration
were designed to limit safety issues for this novel therapy,” said Dr. Sue
Currie, COO of Virion, and one of the study authors. “We look forward to
sharing these late breaking clinical HBV data at APASL, one of the leading
meetings on the treatment of liver diseases in the world.”
LAVA Therapeutics
N.V. (NASDAQ: LVTX), recently announced that
it has entered into a clinical trial collaboration and supply agreement with Merck
& Co., Inc. (NYSE: MRK), Rahway,
NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in
combination with LAVA-1207, a Gammabody® designed to
target the prostate-specific membrane antigen (PSMA) to trigger the potent and
preferential killing of PSMA-positive tumor cells, in patients with therapy
refractory metastatic castration-resistant prostate cancer (mCRPC).
Under the terms of the agreement, Merck & Co., Inc., Rahway,
NJ, USA will provide pembrolizumab for the dose escalation and expansion phases
of LAVA’s ongoing Phase 1/2a study of LAVA-1207 (NCT05369000), with
the combination arm expected to be initiated in the first half of 2024.
Enrollment and dose escalation will also continue in the LAVA-1207 monotherapy
and interleukin-2 arms of the study.
“We are excited to work with Merck & Co., Inc., Rahway, NJ,
USA as we continue to unlock the therapeutic potential of LAVA-1207 and explore
its potential capabilities in combination with KEYTRUDA®,” said Stephen Hurly,
President and Chief Executive Officer, LAVA. “To date, LAVA-1207 has demonstrated
a favorable safety profile and shown preliminary signs of anti-tumor activity.
Prostate cancer has presented challenges for immune checkpoint therapies in the
past – we are hopeful the combination of our products may deliver important
clinical outcomes.”
AbbVie Inc. (NYSE: ABBV) and
OSE Immunotherapeutics SA, a clinical-stage immunotherapy
company, recently announced a
strategic partnership to develop OSE-230, a monoclonal antibody designed to
resolve chronic and severe inflammation, currently in the pre-clinical
development stage.
OSE-230 is a first-in-class monoclonal antibody designed to
activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation
of ChemR23 may offer a novel mechanism for the resolution of chronic
inflammation, modulating functions of both macrophages and neutrophils.
“This collaboration underscores our commitment to expanding our
immunology portfolio with the ultimate goal of improving the standard of care
for patients living with inflammatory diseases globally,” said Jonathon
Sedgwick, Ph.D., senior vice president and global head of discovery research,
AbbVie. “By leveraging our expertise in immunology drug development, we
look forward to advancing OSE-230, which offers a novel mechanism-of-action to
treat chronic inflammation.”
“We are very pleased to collaborate with AbbVie, a global leader
in the development and commercialization of innovative medicines, to drive our
OSE-230 program forward,” said Nicolas Poirier, chief executive officer,
OSE Immunotherapeutics. “This partnership represents a major milestone in our
company’s progress and recognizes the value of our innovative R&D
capabilities. I would like to thank all our employees who helped us reach this
milestone through dedication and hard work.”
About FN Media Group:
At FN Media Group, via our top-rated online news portal at
www.financialnewsmedia.com, we are one of the very few select firms providing
top tier one syndicated news distribution, targeted ticker tag press releases
and stock market news coverage for today’s emerging companies.
Follow us on Facebook to
receive emerging news updates: https://www.facebook.com/financialnewsmedia
Follow us on Twitter for real
time Breaking News: https://twitter.com/FNMgroup
Follow and us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/
DISCLAIMER: FN Media Group LLC (FNM), which owns and
operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party
publisher and news dissemination service provider, which disseminates
electronic information through multiple online media channels. FNM is NOT
affiliated in any manner with any company mentioned herein. FNM and its
affiliated companies are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNM’s market
updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this
release is intended to be strictly informational and is NEVER to be construed
or interpreted as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content and details
which were previously disseminated by the companies mentioned in this
release. FNM is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks. For current services
performed FNM was compensated forty nine hundred dollars for news coverage of
the current press releases issued by Oncolytics Biotech® Inc.
by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY
NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. “Forward-looking statements” describe
future expectations, plans, results, or strategies and are generally preceded by
words such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”. You are
cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors, and
other risks identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements
included herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date hereof and
FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE: FN Media Group
